The BAIAP2 Knockout SK-HEP-1 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population targeting the BAIAP2 gene (also known as IRSp53) in the human SK-HEP-1 liver adenocarcinoma epithelial cell line. This product provides a genetically disrupted mixed population of cells, enabling loss-of-function studies of the BAIAP2 adaptor protein without clonal selection. The polyclonal format preserves population heterogeneity while allowing investigation of BAIAP2-dependent functions in a cellular context relevant to hepatic malignancies. Researchers can employ this model to dissect signaling pathways governing actin cytoskeleton reorganization, cell motility, and metabolic regulation, leveraging the well-characterized SK-HEP-1 background for cancer biology applications.
SK-HEP-1 cells were originally derived from the ascitic fluid of a 52-year-old Caucasian male diagnosed with liver adenocarcinoma, and they are widely utilized as an epithelial cell model for hepatocyte function, hepatocellular carcinoma progression, and liver metastasis. These adherent cells exhibit a hybrid endothelial/epithelial phenotype and express markers of both mesenchymal and hepatic lineages, making them valuable for studying tumor cell plasticity and metastatic dissemination. The SK-HEP-1 line retains key signaling pathways relevant to liver cancer, including those involving insulin and growth factor receptors, and has been extensively characterized in cell migration, invasion, and glucose metabolism assays. Its tumorigenic properties and ease of genetic manipulation render it an ideal host for gene knockout approaches aimed at uncovering molecular mechanisms of liver cancer aggressiveness.
BAIAP2/IRSp53 is an adaptor protein that functions immediately downstream of activated small GTPases, primarily Cdc42 and Rac1, linking them to actin nucleation-promoting factors. It interacts directly with the WAVE1 and WAVE2 regulatory complexes, EPS8, Mena, and VASP to facilitate Arp2/3-mediated actin polymerization, thereby driving filopodia and lamellipodia formation and regulating cell migration. In addition, BAIAP2 participates in insulin signaling by coupling receptor activation to GLUT4 translocation and glucose uptake, with upstream regulators including insulin, IGF-1, PI3K, and TrkB. The protein also binds to synaptic scaffolding molecules such as SHANK and PSD-95 in neuronal contexts, though its role in cancer cells predominantly involves cytoskeletal dynamics and metabolic control. Disruption of BAIAP2 thus uncouples receptor-proximal signals from the WAVE?CArp2/3?CF-actin axis, impairing coordinated membrane protrusion and directional motility.
In the SK-HEP-1 liver adenocarcinoma model, loss of BAIAP2 function is particularly informative for dissecting the mechanisms that underlie hepatocellular carcinoma invasiveness and metastatic potential. By eliminating the adaptor that bridges Cdc42/Rac1 to actin remodeling machineries, these polyclonal knockout cells provide a system to examine how tumor cells rewire their cytoskeletal regulation during epithelial?Cmesenchymal transition, transendothelial migration, and colonization of distant sites. Moreover, the SK-HEP-1 background allows assessment of BAIAP2’s contribution to insulin-responsive glucose transport, a process often dysregulated in cancer metabolism. Combining this knockout model with specific stimuli (e.g., insulin, growth factors) enables quantitative analysis of signal transduction from activated receptors to membrane ruffling and nutrient uptake, offering insights into therapeutic vulnerabilities in liver cancer.
Researchers can employ the BAIAP2 Knockout SK-HEP-1 Polyclonal Cells in a variety of experimental paradigms, including Transwell migration and invasion assays to quantify motility deficits, immunofluorescence microscopy to visualize actin cytoskeleton architecture, and glucose uptake measurements to evaluate insulin signaling integrity. The cells are also suitable for biochemical approaches such as co-immunoprecipitation of WAVE complex components, phospho-Akt analysis upon insulin stimulation, and qPCR profiling of downstream effector expression. Furthermore, this knockout population can serve as a screening tool for small-molecule inhibitors targeting migration or metastasis, providing a genetically defined comparator for drug efficacy studies. For additional technical specifications, protocols, or ordering information, please contact Ascent Research.
